alliance for regenerative medicine

13
May 2015
0 Comments

The state of regenerative medicine industry: ARM report

Posted by

The Alliance for Regenerative Medicine (ARM), a global advocacy organization active since 2009, has recently published the ARM Quarterly Data Report on the state of regenerative medicine industry.…

The Alliance for Regenerative Medicine (ARM), a global advocacy organization active since 2009, has recently published the ARM Quarterly Data Report on the state of regenerative medicine industry.

The report includes analysis of trends and metrics provided by 580 therapeutic companies worldwide. More than 300 of these companies are located in North America.

“This sector has come off a strong year in 2014 and 2015 is off to an even stronger start. As 2015 continues to unfold, we anticipate more high-value deals, and increased investor and public interest in what advanced therapies can offer.” Patricia Reilly and Nancy Dvorin from Informa Business Intelligence, Pharma and Healthcare, ARM’S data partner, wrote in the report.

Higher investments in advanced therapies are in fact among the major trends of the first quarter of 2015. Currently, 486 clinical trials (phase I, II or III) are underway. More than 1/3 of current clinical trials are in oncology, and more than 1/10 are in the cardiovascular area.

Source: Alliance for Regenerative Medicine

Current Clinical Trials by Therapeutic Category. Source: ARM Quarterly Data Report

Additional ARM reports, released at the end of each quarter of the year, will include updates to the current information. To view and download the Q1 Report click here.

Click to read more Close
21
Mar 2014
0 Comments
ARM

The United States takes a step forward in regenerative medicine

Posted by

The United States has moved a step forward toward the creation of a national strategy to support research in regenerative medicine.…

The United States has moved a step forward toward the creation of a national strategy to support research in regenerative medicine.

On March 13, The Alliance for Regenerative Medicine (ARM) announced the introduction of the Regenerative Medicine Promotion Act of 2014.

The ARM is a global advocacy organization and the U.S. national voice for promotion of legislative, regulatory and reimbursement initiatives to accelerate the development of regenerative medicine technologies.

The new bill, supported by the U.S. Senators Barbara Boxer and Mark Kirk, seeks to advance research in regenerative medicine in the United States.

“Regenerative medicine gives priceless hope to millions of Americans who are suffering from life-threatening or debilitating conditions,” says Senator Boxer in the Senate Press Release.

“As a stroke survivor, I know first hand the importance of medical research and therapy,” adds Senator Kirk.

Regenerative medicine has the potential of regenerating tissues and organs by using techniques that will replace damaged tissues or organs with healthy ones. Many diseases, such as Alzheimer’s, cancer, diabetes, heart disease, renal failure and osteoporosis may one day be cured through regenerative medicine.

“Regenerative medicine represents the single most promising new approach to mitigating the humans and economic costs of disease, and changing the course of human health,” says Michael Werner, Executive Director of ARM, in the official ARM press release.

ARM contends that further development of the research in regenerative medicine requires a strong federally-directed initiative. It calls for a cohesive governmental policy and funding, and collaboration among scientists, so that regenerative medicine can one day become the standard of care.

The proposed legislation would create a Regenerative Medicine Coordinating Council within the U.S. Department of Health and Human Services (HHS). The Council, which will include the Cabinet secretaries, agency heads, researchers and other experts and advocates will work on the development of a national strategy for regenerative medicine and identify policy priorities. In addition, the U.S. Government Accountability Office will issue a detailed report on the undergoing federal programs in the field of regenerative medicine.

“A coordinated effort, such as the one outlined in the bill introduced today, will allow us to advance toward innovative, life-saving therapies and create the regulatory infrastructure necessary to encourage private investment in promising regenerative medicine research,” says Morrie Ruffin, Managing Director of ARM, in the ARM press release.

To see the progress made in the development of a Canadian National Stem Cell Strategy click here.

Click to read more Close
Back to Top